Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Mayo Clinic

Sites in Rochester, MN

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1824
Shown on this page
12
Current sort
Recently updated
Campus scope
Mayo Clinic, Rochester, MN
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Mayo Clinic, Rochester, MN. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 1093–1104 of 1,824 matching trials with a site at Mayo Clinic, Rochester, MN.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 1Phase 2 Interventional

CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer

NCT07322094
Status at this site: Recruiting
View directory record Official record
Conditions
FIGO Stage III and IV Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer
Interventions
TORL-1-23 and paclitaxel, TORL-1-23 and carboplatin, TORL-1-23, paclitaxel, and carboplatin
Combination Product
Lead sponsor
TORL Biotherapeutics, LLC
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Fullerton, California • Irvine, California • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Nov 7, 2026, 6:16 PM EST
Active, not recruiting Not applicable Interventional

AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion

NCT06029660
Site status not listed — check the official record
View directory record Official record
Conditions
Aortic Aneurysm, Abdominal
Interventions
IMPEDE-FX RapidFill Implants, EndoVascular Aneurysm Repair
Device · Procedure
Lead sponsor
Shape Memory Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
39
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Nov 7, 2026, 6:16 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

NCT05726864
Site status not listed — check the official record
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R, KRAS G12V, KRAS G12A, KRAS G12C, KRAS G12S, KRAS G13D, NRAS G12D, NRAS G12R, NRAS G12V, NRAS G12C, NRAS G12S
Interventions
ELI-002 7P
Drug
Lead sponsor
Elicio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
28
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Nov 7, 2026, 6:16 PM EST
Recruiting No phase listed Observational

Rare Kidney Stone Consortium Patient Registry

NCT00588562
Status at this site: Recruiting
View directory record Official record
Conditions
Primary Hyperoxaluria, Dent Disease, Cystinuria, APRT Deficiency
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
0 Years to 100 Years
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2028
U.S. locations
3
States / cities
Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Nov 7, 2026, 6:16 PM EST
Recruiting Not applicable Interventional

MyokinE100 System: Closed Loop Electrical Muscle Stimulation to Mitigate ICU Acquired Weakness in Medical ICU Patients

NCT07362862
Status at this site: Recruiting
View directory record Official record
Conditions
Sepsis, Critical Illness, ICU-acquired Muscle Weakness, ICU-acquired Weakness, ICUAW, Sarcopenia, Secondary Sarcopenia
Interventions
Electrical Muscle Stimulation System
Device
Lead sponsor
Health Discovery Labs
Industry
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Rochester, Minnesota • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Nov 7, 2026, 6:16 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Acceptability of Testing DNA Markers in Vaginal Fluid for the Detection of Endometrial Cancer

NCT07527143
Status at this site: Recruiting
View directory record Official record
Conditions
Endometrial Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
45 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Nov 7, 2026, 6:16 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Time-Efficient Inspiratory Muscle Strength Training for Reducing Sympathetic Activity and Improving Sleep in Midlife Women

NCT06743269
Status at this site: Recruiting
View directory record Official record
Conditions
Menopause, Hot Flashes, Blood Pressure Regulation
Interventions
High-Resistance Inspiratory Muscle Strength Training, Low-Resistance Inspiratory Muscle Strength Training, POWERbreathe K3 device
Behavioral · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Nov 7, 2026, 6:16 PM EST
Recruiting No phase listed Observational

A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes

NCT07203768
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Polycythemia Vera, Thrombocythemia
Interventions
Not listed
Lead sponsor
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Other
Eligibility
18 Years to 100 Years
Enrollment
678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Nov 7, 2026, 6:16 PM EST
Active, not recruiting Phase 2 Interventional

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

NCT05607004
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer
Interventions
(Z)-endoxifen, goserelin
Drug
Lead sponsor
Atossa Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
14
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Nov 7, 2026, 6:16 PM EST
Active, not recruiting Phase 2 Interventional

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

NCT03269669
Site status not listed — check the official record
View directory record Official record
Conditions
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
Interventions
Bendamustine Hydrochloride, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Lenalidomide, Multigated Acquisition Scan, Obinutuzumab, Positron Emission Tomography, Prednisone, Umbralisib, Vincristine Sulfate
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
429
States / cities
Anchorage, Alaska • Tucson, Arizona • Anaheim, California + 292 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Nov 7, 2026, 6:16 PM EST
Active, not recruiting Not applicable Interventional

Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial

NCT03706833
Site status not listed — check the official record
View directory record Official record
Conditions
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
Interventions
Edwards PASCAL System, Abbott Mitraclip System
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
18 Years and older
Enrollment
1,247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
63
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Nov 7, 2026, 6:16 PM EST
Active, not recruiting Phase 2 Interventional

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

NCT04291105
Site status not listed — check the official record
View directory record Official record
Conditions
Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
Interventions
VV1, Cemiplimab
Biological
Lead sponsor
Vyriad, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Santa Monica, California • New Haven, Connecticut • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Nov 7, 2026, 6:16 PM EST

About this Mayo Clinic institution page

What this page lists
ClinicalTrials.gov records that list Mayo Clinic in Rochester, MN as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Mayo Clinic at any site, browse by condition, or browse by U.S. city.